New research highlights amivantamab's potential in enhancing treatment outcomes for RAS/BRAF wild-type metastatic colorectal cancer, addressing resistance to standard therapies.
Filippo Pietrantonio, MD
Advertisement
Articles by Filippo Pietrantonio, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
The Targeted Pulse: Lung Cancer Advancements and FDA Decisions
2
Antitumor Activity Seen With Targeted Alpha Therapy [212Pb]VMT-α-NET in SSTR2+ NETs
3
Nivolumab Outperforms Brentuximab Vedotin in PFS in Classic Hodgkin Lymphoma
4
Savolitinib/Osimertinib Extends PFS in MET-Amplified EGFR-Mutated NSCLC
5